Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TB therapy following drug-induced liver injury
ISRCTN92067975Phase 4Completed
- Sponsor
- Nottingham Clinical Trials Unit
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ethambutol, isoniazid, rifampicin and pyrazinamide in Tuberculosis (TB) (2 arms), sponsored by Nottingham Clinical Trials Unit. Primary endpoint: DILI recurrence within 12 months following randomisation. Started Aug 2022; status: completed.
02
Drugs
ethambutolisoniazidrifampicinpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ISRCTN92067975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92067975.